Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 5/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610461 | 0.80 | IDO1 (0.57) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL24590336 | 0.79 | TSHR (0.44) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL12502485 | 0.77 | IDO1 (0.53) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL682849 | 0.77 | IDO1 (0.53) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL6525289 | 0.77 | IDO1 (0.53) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL7492817 | 0.77 | IDO1 (0.53) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL28885907 | 0.76 | IDO1 (0.52) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL19725366 | 0.75 | HTT (0.50) | IDO1AGXTSLC6A4 | |
| SCHEMBL936399 | 0.75 | IDO1 (0.55) | IDO1AGXTSLC6A4CA1CA2 | |
| SCHEMBL19725384 | 0.74 | IDO1 (0.50) | IDO1AGXTSLC6A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | CALD1, CALU, STT3A | IDO1 4510/4885AGXT 3708/4885SLC6A4 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.